ARS Pharmaceuticals, Inc. Logo

ARS Pharmaceuticals, Inc.

Develops the first FDA-approved, needle-free epinephrine spray for severe allergic reactions.

SPRY | US

Overview

Corporate Details

ISIN(s):
US82835W1080
LEI:
Country:
United States of America
Address:
11682 EL CAMINO REAL, SUITE 300, 92130 SAN DIEGO
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

ARS Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of treatments for patients with severe allergic reactions. The company is dedicated to creating patient-friendly, needle-free therapies to address challenges such as device portability, ease of use, and needle-related risks. Its lead product, neffy® (epinephrine nasal spray), is the first and only FDA-approved needle-free epinephrine product for the emergency treatment of Type I allergic reactions. neffy is designed as a non-invasive and easy-to-carry alternative to traditional auto-injectors, empowering patients and caregivers to administer treatment without hesitation.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all ARS Pharmaceuticals, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for ARS Pharmaceuticals, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for ARS Pharmaceuticals, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
OliX Pharmaceuticals, Inc. Logo
Developing RNAi therapeutics for dermatology, ophthalmology, and metabolic diseases via an asiRNA platform.
South Korea 226950
OMEROS CORP Logo
Develops first-in-class therapeutics for challenging diseases with unmet medical needs.
United States of America OMER
ONCODESIGN Logo
Developing precision oncology solutions for resistant and metastatic cancers.
France ALONC
Oncodesign Precision Medicine S.A Logo
Develops precision therapies & diagnostics for resistant and metastatic cancers.
France ALOPM
Oncoinvent ASA Logo
Developing alpha-emitting radiotherapies for treating cancers in the peritoneal cavity.
Norway OCIN
Oncolys BioPharma Inc. Logo
Developing oncolytic virus therapies and diagnostics for cancer and serious viral infections.
Japan 4588
ONCOLYTICS BIOTECH INC Logo
Developing an immuno-oncolytic virus to treat breast and gastrointestinal cancers.
United States of America ONCY
Onconetix, Inc. Logo
Develops diagnostics and therapeutics for men's health and oncology markets.
United States of America ONCO
Oncopeptides Logo
Develops targeted therapies for hematological cancers using peptide-drug conjugate technology.
Sweden ONCO
Onesano S.A. Logo
Develops patented nutritional products for humans, animals, and agriculture.
Poland SKT

Talk to a Data Expert

Have a question? We'll get back to you promptly.